系统性红斑狼疮患者外周血Th17细胞与调节性T细胞的变化

目的 探讨外周血辅助性T细胞17(Th17)与调节性T细胞在系统性红斑狼疮(SLE)发生、发展中的变化.方法 选取32例SLE活动期患者作为SLE活动组、30例SLE稳定期患者作为SLE稳定组及25名健康者作为对照组,采用流式细胞术及定量聚合酶链反应(PCR)的方法,分别从蛋白质水平与mRNA水平检测其外周血CD4+T细胞IL-17及FoxP3的表达.采用单因素方差分析进行统计学处理.结果 SLE活动组外周血CD4+T细胞IL-17蛋白质(1.01±0.22)％及mRNA(2.04±0.63)表达水平显著高于SLE稳定组(0.48±0.16)％、(1.12±0.34)及健康对照组(0.41±0.12)％、1(P＜0.01),但SLE稳定组与健康者对照组差异无统计学意义(P＞0.05).SLE活动组外周血CD4+T细胞FoxP3蛋白质(2.36±0.54)％及mRNA(0.42±0.16)表达水平显著低于SLE稳定组(4.34±0.95)％、(0.87±0.28)及健康对照组(5.09±1.17)％、 1(P＜0.01),SLE稳定组又低于健康对照组(P＜0.05).结论 SLE患者外周血中可能存在Th17/调节性T细胞的失衡,且失衡程度可能与病情活动性相关.

The profile of Th17/Treg balance in the peripheral blood of patients with systemic lupus erythematosus

Objective To investigate the profile of Th17/Treg balance in the peripheral blood of patients with systemic lupus erythematosus (SLE).Methods Thirty-two SLE patients in active disease were selected and 30 SLE patients in remission were included in this study.The control group was consisted of 25healthy individuals.The expressions of IL-17 and FoxP3 on CD4+ T cells in the peripheral blood were assessed by flow cytometry and the mRNA levels of these two cytokines were examined by quantitative PCR respectively.ANOVA was used for statistical analysis.Results The percentage of CD4+IL-17+ T cells and IL-17mRNA expression of the active group were significantly higher than those of the remission group and control group(l.0l±0.22)％,(2.04±0.63)vs (0.48±0.16)％,(1.12±0.34) vs (0.41±0.12)％,1; P＜0.01].There was no difference between the remission group and control group (P＞0.05).However,the percentage of CI4+FoxP3 + T cells and FoxP3 mRNA expression of the active group were significantly lower than those of the remission group and control group (2.36±t0.54)％,(0.42±0.16) vs (4.34±0.95)％,(0.87±t0.28) vs (5.09±11.17)％,1; P＜0.01 ],and there was also significant differences between the remission group and control group (P＜0.05).Conclusion Thl7/Treg balance shift may exist in the peripheral blood of patients with SLE and the degree of imbalance may be related to disease activity of SLE.